In October 2016, the Center for Diagnostics and Therapeutics (CDT) of the American Gastroenterological Association (AGA) held its first Drug Development Conference. Over a 2-day period, researchers, clinicians, Food and Drug Administration (FDA) personnel, and representatives of the pharmaceutical industry and patient advocacy groups convened in Washington, DC, to discuss current unmet needs and future strategies in 4 disorders of the upper gastrointestinal (GI) tract. The 4 disorders discussed were gastroesophageal reflux disease (GERD), eosinophilic esophagitis, gastroparesis, and functional dyspepsia.